Intellia Therapeutics Inc (NTLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 4:41 PM ET
Intellia Therapeutics Inc (NTLA) Stock Chart
Intellia Therapeutics (NTLA) has a latest price of $9.78 on Nov 17, 2026, 47.1% below its 52-week high of $18.48. Its price rose 12.4% over the past 12 months. The month-end price fell 9.5% over the 10 years through Oct 2026, a compound annual decline of 1.0%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $161.91 in Jun 2021 and its lowest $6.87 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NTLA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NTLA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 26.4%, and over 6 months it fell 18.1%. The month-end price fell 50.2% over the 3 years through Oct 2026, a compound annual decline of 20.7%.
| Period | Change |
|---|---|
| 1 month | -15.5% |
| 3 months | -26.4% |
| 6 months | -18.1% |
| 12 months | +12.4% |
| 12 months, with dividends | +12.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -50.2% | -20.7% |
| 5 years | -90.6% | -37.7% |
| 10 years | -9.5% | -1.0% |
Price by Year
Its best calendar year was 2020, when the price rose 270.8%, and its weakest was 2022, when it fell 70.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $12.47 | +38.7% |
| 2025 | $8.99 | -22.9% |
| 2024 | $11.66 | -61.8% |
| 2023 | $30.49 | -12.6% |
| 2022 | $34.89 | -70.5% |
| 2021 | $118.24 | +117.4% |
| 2020 | $54.40 | +270.8% |
| 2019 | $14.67 | +7.5% |
| 2018 | $13.65 | -29.0% |
| 2017 | $19.22 | +46.6% |
Trading Range
The price is 17.1% below its 50-day average of $11.80 and 24.3% below its 200-day average of $12.92.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $9.78 | |
| 52-week high | $18.48 | -47.1% |
| 52-week low | $7.95 | +23.0% |
| 50-day average | $11.80 | -17.1% |
| 200-day average | $12.92 | -24.3% |
Price Risk
Over 3 years, its largest fall from a peak was 80.9%.
| Measure | Value |
|---|---|
| 1-year beta | 2.32 |
| Largest fall, 1 year | -45.6% |
| Largest fall, 3 years | -80.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NTLA
What is NTLA's 1-year price change?
Intellia Therapeutics's price rose 12.4% over the past 12 months. With dividends included, the 12-month total return was 12.4%.
What is NTLA's 5-year price change?
Intellia Therapeutics's month-end price fell 90.6% over the 5 years through Oct 2026, a compound annual decline of 37.7%. These figures leave out dividends.
What is NTLA's 52-week high and low?
Intellia Therapeutics's 52-week high is $18.48 and its 52-week low is $7.95. Its latest price of $9.78 on Nov 17, 2026 is 47.1% below the high.
What is NTLA's beta?
Intellia Therapeutics's 1-year beta against the S&P 500 is 2.32, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.6%.
Is the NTLA chart free?
Yes. Advanced Charting for NTLA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NTLA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors